Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers

Joeres-Nguyen-Xuan, Thai Hoa; Boehm, Stephan; Joeres, Lars; Schulze, J.; Kruis, Wolfgang

doi:10.1002/ibd.21042

Cited by 47 publications

(34 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, after administration is terminated, both probiotics are cleared from the majority of patients within weeks. In a study of 48 healthy adult individuals who were administered E. coli Nissle for a run-in period of 17 days, only approximately 45% of the individuals had detectable levels of the probiotic two weeks after stopping administration 79 . This number continued to drop continuously until the probiotic was undetectable in nearly all individuals after 48 weeks.…”

Section: Promoting Growth and Colonization By Beneficial Bacteriamentioning

confidence: 99%

The Yin and Yang of Bacterial Resilience in the Human Gut Microbiota

Gibson

Pesesky

Dantas

2014

Journal of Molecular Biology

View full text Add to dashboard Cite

The human gut is home to trillions of microbes that form a symbiotic relationship with the human host. During health, the intestinal microbiota provides many benefits to the host and is generally resistant to colonization by new species; however, disruption of this complex community can lead to pathogen invasion, inflammation, and disease. Restoration and maintenance of a healthy gut microbiota composition requires effective therapies to reduce and prevent colonization of harmful bacteria (pathogens) while simultaneously promoting growth of beneficial bacteria (probiotics). Here we review the mechanisms by which the host modulates the gut community composition during health and disease, and discuss prospects for antibiotic and probiotic therapy for restoration of a healthy intestinal community following disruption.

show abstract

Section: Promoting Growth and Colonization By Beneficial Bacteriamentioning

confidence: 99%

The Yin and Yang of Bacterial Resilience in the Human Gut Microbiota

Gibson

Pesesky

Dantas

2014

Journal of Molecular Biology

View full text Add to dashboard Cite

show abstract

“…Differences between the groups were not significant. At treatment discontinuation, 16/20 volunteers in the mesalamine group and 15/20 volunteers in the placebo group were EcN positive, whereas this figure dropped continuously up to week 12 after discontinuation [35]. It seems that the combination of EcN and mesalamine has no significant effect on the survival of EcN in healthy volunteers.…”

Section: Efficacy Of Probiotics In Ibdmentioning

confidence: 91%

The Role of Pre- and Probiotics in the Treatment of Inflammatory Bowel Disease

Triantafillidis¹

2011

J Microbial Biochem Technol

View full text Add to dashboard Cite

Many patients with inflammatory bowel disease use alteranative therapy, mainly probiotics and synbiotics, to manage this intestinal condition. Despite widespread use of these natural therapies by patients, health care providers may be unfamiliar with probiotics as a treatment modality. This review describes the rationale for use of probiotics in patients with active or inactive inflammatory bowel disease, their mechanism(s) of action, and recent controlled clinical studies in which efficacy of probiotics, prebiotics and synbiotics in patients with active or inactive inflammatory bowel disease has been explored. Certain probiotics, particularly E. coli Nissle 1917 and a multi-agent mixture VSL#3, may be benefit patients with UC or pouchitis, while LactoBacillus rhamnosus GG appears less useful. In general, probiotics show potential for therapeutic application mainly in pouchitis and to a lesser degree in UC, while their effects in maintenance therapy for CD have been much less promising. While there is suggestion of benefit when patients with ulcerative colitis use bacterial therapies small sample sizes and methodological weeknesses in study designs necessitate that additional studies must be conducted before probiotics and or synbiotics can be routinely recommended in clinical practice.

show abstract

“…For instance, many current efforts for recombinant therapies have employed L. lactis , a bacterium that does not colonize the mammalian intestine, as a chassis for therapeutic protein production [84–86,88,92]. Likewise, the common chassis, E. coli Nissle 1917, shows greatly variable colonization capacity in different healthy individuals following daily probiotic treatment; fewer than 50% of volunteers became decolonized two weeks after cessation of treatment, whereas the probiotic was detectable by PCR in the stool of only 17.5% of volunteers after 6 months [133]. However, stable engraftment of cell-based therapies into the endogenous microbiota may increase the efficacy of treatment and enable the development of long-term, fully autonomous, disease-responsive therapies.…”

Section: Challenges and Outlook In The Development Of Microbiota-bmentioning

confidence: 99%

Microbiome therapeutics — Advances and challenges

Mimee

Citorik

2016

Advanced Drug Delivery Reviews

222

155

View full text Add to dashboard Cite

The microbial community that lives on and in the human body exerts a major impact on human health, from metabolism to immunity. In order to leverage the close associations between microbes and their host, development of therapeutics targeting the microbiota has surged in recent years. Here, we discuss current additive and subtractive strategies to manipulate the microbiota, focusing on bacteria engineered to produce therapeutic payloads, consortia of natural organisms and selective antimicrobials. Further, we present challenges faced by the community in the development of microbiome therapeutics, including designing microbial therapies that are adapted for specific geographies in the body, stable colonization with microbial therapies, discovery of clinically relevant biosensors, robustness of engineered synthetic gene circuits and addressing safety and biocontainment concerns. Moving forward, collaboration between basic and applied researchers and clinicians to address these challenges will poise the field to herald an age of next-generation, cellular therapies that draw on novel findings in basic research to inform directed augmentation of the human microbiota.

show abstract

Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers

Abstract: The combination of EcN and mesalamine has no significant effect on the survival of EcN in healthy volunteers.

Cited by 47 publications

References 22 publications

The Yin and Yang of Bacterial Resilience in the Human Gut Microbiota

The Yin and Yang of Bacterial Resilience in the Human Gut Microbiota

The Role of Pre- and Probiotics in the Treatment of Inflammatory Bowel Disease

Microbiome therapeutics — Advances and challenges

Contact Info

Product

Resources

About